In the Methods section of the article, the numerical value defining the fatty liver index cutoff was inadvertently misstated. Specifically, the cutoff was written as “≥60” when it should have been “≥30,” as used correctly in all analyses.
We would like to clarify that this error was typographical in nature and does not affect the results, interpretations, or conclusions of the study.
Before correction
Classification of change in MASLD status
The FLI efficiently identifies NAFLD in European and Asian populations, and previous studies have also adopted FLI in the operational definition of steatotic liver disease status [22-25]. MASLD was defined as steatotic liver disease (FLI ≥60) [26] and the presence of at least one of the following cardiometabolic risk factors: body mass index (BMI) ≥23 kg/m2 or waist circumference ≥90 cm (for men) and ≥85 cm (for women) [27], fasting serum glucose ≥100 mg/dL or a history of antidiabetic drug prescription or type 2 diabetes, blood pressure ≥130/85 mm Hg or a history of antihypertensive drug prescription, triglycerides ≥150 mg/dL or a history of lipid-lowering drug prescription, and high-density lipoprotein cholesterol ≤40 mg/dL (for men) and ≤50 mg/dL (for women) [20].
After correction
Classification of change in MASLD status
The FLI efficiently identifies NAFLD in European and Asian populations, and previous studies have also adopted FLI in the operational definition of steatotic liver disease status [22-25]. MASLD was defined as steatotic liver disease (FLI ≥30) [26] and the presence of at least one of the following cardiometabolic risk factors: body mass index (BMI) ≥23 kg/m2 or waist circumference ≥90 cm (for men) and ≥85 cm (for women) [27], fasting serum glucose ≥100 mg/dL or a history of antidiabetic drug prescription or type 2 diabetes, blood pressure ≥130/85 mm Hg or a history of antihypertensive drug prescription, triglycerides ≥150 mg/dL or a history of lipid-lowering drug prescription, and high-density lipoprotein cholesterol ≤40 mg/dL (for men) and ≤50 mg/dL (for women) [20].